ATTORNEY DOCKET NO. 00786/263003

Certificate of Mailing: Date of Deposit:
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal
Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant
Commissioner of Patents, Washington, D.C. 20231.

Colleen Covne

Printed name of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Serial No.:

Filed:

Title:

Frederick M. Ausubel et al.

08/962,750

Examiner: R. Swartz

November 3, 1997

METHODS OF SCREENING COMPOUNDS USEFUL FOREMARK 12000

PDEVENTION OF INFECTION OR PATHOGENICITY

Assistant Commissioner of Patents Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO 1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed after a final Office action but before payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, dated December 9, 1999, which is not more than three months prior to the filing of this statement. Applicant hereby petitions under §1.97(d)(2) for this statement to be considered. A check for the \$130 petition fee of §1.17(i) is also enclosed.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Karen L. Elbing, Ph.D. James De Camp Reg. No. 35,238 Reg. No. 43,580

Clark & Elbing LLP 176 Federal Street

Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

\Ceserver\documents\00786\263xxx\00786.263003 Supplemental Information Disclosure Statement.wpd

JAN 0 6 2000 EE

Sheet __1__ of __1__

SUBSTITUTE (MODIFIED)	FORM PTO-1449	U.S. DEPARTMENT OF COMMERC PATENT AND TRADEMARK OFFICE		Attorney Docket No.		00786/263003		
(WODIFIED)	Serial No.		08/962,750					
INFORMATION DISCLOSURE					Applicant		Frederick M. Ausubel et al.	
STATEMENT BY APPLICANT (Use several sheets if necessary)				Filing Date		November 3, 1997		
				Group		1641		
(37 CFR §1.98(b))				IDS Filed		January 03, 2000		
U.S. PATENTS								
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION								
Examiner's Initials	· · · · · · · · · · · · · · · · · · ·)	Class	Subclass	Translation (Yes/No)		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)								
Cohn et al., "The Effect of Amiloride on Pigment Expression in a Clinical Isolate of <i>Pseudomonas Aeruginosa</i> ," Current Therapeutic Research 51:562-567 (1992).								
Conrad et al., "Efficacy of Aztreonam in the treatment of skeletal infections due to Pseudomonas aeruginosa," Review of Infectious Diseases 13:S634-S639 (1991).								
				-				
EXAMINER DATE				ONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.								